MARKET WRAP-UP TH NOVEMBER 7 2016

Bulgaria MACRO 120

Socialist’s Radev won first round in 115 presidential elections 110

105 Socialists backed Rumen Radev won the first round of Bulgaria’s 2016 Presidential Elections. Radev won 100 25.63% of the votes under high voters’ turnout of 54%, 95 according to preliminary results. Ruling party GERB backed candidate – Tsetska Tsacheva, came second with 22.03% of 90 the vote. Radev and Tsacheva to go on a second round of 85 voting in a week – next Sunday, November 13th. Nationalist’s backed Krasimir Karakachanov and populist Veselin Mareshki scored third and fourth, respectively, with SOFIX MSCI FM+CIS /eur/

10%+ while MRV backed Plamen Oresharski and rightest Source: Bloomberg Traycho Traykov came out with very close results for the fifth and sixth place, respectively with 6%+ of the votes. OVERALL MARKET DATA No immediate effect on the government so far with the Prime Minister postponing potential government Total Market Cap: 8.59 b resignation until the results of the second elections round next Total Turnover (FY 2015, regulated market) 410 m Sunday. At the start of the presidential campaign Borisov said Average Daily Turnover (FY 2015, regulated market) 1.66 m the government would resign if Tsacheva is not first on the Figures are in Bulgarian lev /BGN/ Source: Bulgarian Stock Exchange first round of elections. Last night, Borisov announce the government would consider resignation depending on second MARKET MULTIPLES round results. Index Last 6M%∆ 12M%∆ P/E P/B D/Y

SOFIX 530.21 19.99% 18.21% 10.29 1.08 4.40% Bulgaria ECM MSCI FM CEE+CIS 286.72 6.50% 2.47% 8.20 0.91 5.94% Source: Bloomberg Sopharma (3JR BU) posts 6% y/y drop in 10M16 TOP 3 MOST ACTIVE DAILY STOCKS revenues on 1% y/y rise in domestic sales and 11% drop in exports, the Company announced in a preliminary Stock Ticker Market Cap Turnover statement to the stock exchange. The latter is a deterioration Velgraf Asset Management 1VX BU 189 m 400 k after the Company announced 3% y/y drop in 9M16 sales on Chimimport 6C4 BU 359 m 89 k 1% y/y rise in domestic sales and 3% y/y drop in exports. Key export fluctuations in 2016 come from Russia as well as Neochim 3NB BU 143 m 61 k Caucasus countries and Kazakhstan. Figures are in Bulgarian lev /BGN/ Source: Bulgarian Stock Exchange Also, Sopharma announce the Company’s board approved the acquisition of local pharma producer Veta Pharma. The ELANA TOP PICKS purchase price approved is no more than BGN 2.12 per share Stock Ticker M Cap Last 1-Yr PT fP/E Reco valuing Veta Pharma at BGN 9.6m or 2x P/B and 4.4x P/S. In Speedy 0SP BU 192 m 36.00 38.42 15.86 HOLD

2015, Veta Pharma booked BGN 2.2m in revenies and BGN Monbat 5MB BU 316 m 8.08 9.05 10.36 BUY 32k in loss. The company is a pharmaceutical manufacturer of Sopharma 3JR BU 397 m 3.02 3.09 9.66 BUY non-sterile medicinal products – powdered products, dermal Sopharma

SO5 BU 194 m 5.90 6.03 13.29 BUY solutions and tinctures for oral use. It also produces food Trading additives and cosmetic products with overall sales at 3 million Bulgarian Real Estate 5BU BU 43 m 2.13 2.70 0.61 BUY packs in 2015. Key shareholders in Veta Pharma are (intr.value.) (p/b) Fund REIT* Sopharma related parties – Telso (20%+), Homogen (16%+), Sirma etc. Group SKK BU 61 m 1.03 1.38 32.80 BUY Holding P/E ratios are on a forward 12M base; figures are in Bulgarian lev /BGN/ th *3-for-1 stock split as of Feb 29 , 2016 LATEST MACRO DATA Indicators Q2 2016 GDP, % y-o-y 3% Inflation, % y-o-y -0.2% Unemployment rate 8.0% Budget balance cash basis, % of GDP 3.7% Net external debt, % of GDP 11.4% Government debt, % of GDP 29.2% Central bank reserves, % of GDP 46% Long-term 10-yr % 2.40% S&P / Fitch Rating BB+/BBB- Source: BNB; NSI; Finance Ministry; Elana trading estimate, Eurostat

EXCHANGE RATES: EUR/BGN:1.95583 (fixed); USD/BGN:1.76312

The Best ELANA Trading Bulgarian Broker www.elana.net/english 2010, 2013, 2014 and 2015

MARKET WRAP-UP TH NOVEMBER 7 2016

Disclaimer

Regulatory Restrictions: No publication of ELANA Trading should be construed as an offer (or solicitation of an offer) to U.S. persons to buy or sell financial instruments or any financial product, make any investment or participate in any particular trading strategy (collectively “Offers”). No Publication of ELANA Trading should be construed as an Offer (or solicitation of an offer) in any jurisdiction in which such Offer would be illegal. Any such perceived Offer will not be honoured by ELANA Trading. Analyst Certification: The research analyst(s) certifies that: (1) all of the views expressed in this document accurately reflect his or her personal views about any and all of the subject securities or issuers; (2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this document. Financial Interest: ELANA trading does and seeks to do business with companies covered in its research reports. This may and includes investment banking services for which ELANA Trading shall be remunerated. ELANA Trading has performed investment banking services for Sirma Group Holding (SKK BU) during the last 12 months for which it was flat remunerated. ELANA Trading acts a market maker for Sirma Group Holding. ELANA Trading has performed investment banking services for Sopharma (3JR BU) for which it was flat remunerated. ELANA Trading may trade or own shares of the analyzed companies. The research analyst(s) is not holding shares of the analyzed companies, unless otherwise noted. As a result, investors should be aware that ЕLANA trading may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Regulatory Authority: Financial Supervisory Commission, Budapest Street 16, 1000 , Bulgaria Information Disclosure: All reasonable care has been taken to ensure the facts stated are accurate and opinions given are fair and reasonable. Our recommendations are based on information available to the public that we consider to be reliable but for the completeness and accuracy of which we assume no liability. Neither ELANA Trading, nor its directors, officers or employees shall in any way be responsible for its contents. The views expressed may differ from the views of other firm departments or representatives. Additional information is available upon request. Unless otherwise noted, sources for all information in charts and tables are ELANA Trading’s calculations. Risks for Investors: Information in this document should not be regarded as an offer to buy or sell any financial instruments. The investment possibilities discussed in this document may not be suitable for certain investors depending on their specific investment objectives and time horizon or in the context of their overall financial situation. In particular, the risks associated with an investment in the securities or the financial instruments under discussion are not explained in its entirety. The prices or values of the securities may go down as well as up and can fluctuate and fall against the investor. The securities or investments may cause the investor to lose the amount invested. Past performance is not a guide to future performance. Changes in exchange rates may have an adverse effect on the value, price or income of the securities or investments. Valuation Methods: Company valuations are based on the following methods: multiple-based (P/E, P/B, EV/EBITDA), historical valuation approaches, peer comparisons, discount models (DCF, DDM) or asset-based evaluation methods. Valuation models are dependent on macroeconomic factors, including interest rates, foreign exchange rates, prices of raw materials, and any expectations about the economy, the market sentiment. The valuation is based on expectations that might change rapidly and without notice, depending on developments specific to individual industries and countries. Recommendations and target prices derived from the models might therefore change accordingly. The application of models depends on forecasts of a range of economic variables, thus there is a range of reasonable variations within models. Any valuation is dependent upon inputs that are based on the subjective opinion of the analysts carrying out this valuation. Recommendations: Analyst(s) recommendations are based on the specific factors for the company, sector, country and global developments, as compared to market indices. Recommendations and opinions reflect ELANA Trading's expectations over the 12-month period following publication from the perspective of long-only investment clients. ELANA Trading reserves the right to express different or contrary recommendations and opinions for different timescales or for other types of investment client. Except as otherwise noted, expected performance over next 12 months vary for different recommendations for Bulgarian stocks as follows:

BUY Target price is more than 10% above current quotes

HOLD Target price in +/-10% range of the current quotes

SELL Target price is more than 10% below the current quotes

Frequency of Recommendations: No schedule of recommendations is available. The frequency of recommendations depends on specific factors to individual companies and the opinion of the analyst(s) for the necessity of minor or major changes. Copyrights: The copyrights of ELANA Trading analyses belong to the Research Department of the brokerage and their content cannot be used for commercial purposes. Replication and redistribution of ELANA Trading analyses content is expressly prohibited without the prior written consent of the appointed contacts listed below.

For more information, please contact:

Research Analyst Phone: E-mail: Internet: Tatyana Vasileva +359 2 810 00 24 [email protected] www.elana.net

The Best ELANA Trading Bulgarian Broker www.elana.net/english 2010, 2013, 2014 and 2015